1. Home
  2. GNW vs LQDA Comparison

GNW vs LQDA Comparison

Compare GNW & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genworth Financial Inc

GNW

Genworth Financial Inc

HOLD

Current Price

$8.79

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$38.27

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNW
LQDA
Founded
1871
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.1B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
GNW
LQDA
Price
$8.79
$38.27
Analyst Decision
Buy
Strong Buy
Analyst Count
1
11
Target Price
$10.50
$41.00
AVG Volume (30 Days)
3.0M
1.0M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.81
EPS
0.54
N/A
Revenue
$7,301,000,000.00
$158,320,000.00
Revenue This Year
N/A
$278.87
Revenue Next Year
N/A
$57.13
P/E Ratio
$16.14
N/A
Revenue Growth
0.08
1031.18
52 Week Low
$6.29
$11.85
52 Week High
$9.28
$46.67

Technical Indicators

Market Signals
Indicator
GNW
LQDA
Relative Strength Index (RSI) 64.57 54.11
Support Level $8.01 $31.75
Resistance Level $8.80 $39.19
Average True Range (ATR) 0.21 1.93
MACD 0.10 0.29
Stochastic Oscillator 88.90 58.78

Price Performance

Historical Comparison
GNW
LQDA

About GNW Genworth Financial Inc

Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has four main operating business segments: Enact, Closed Block segment, and Corporate and Other. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. The majority of the revenue is generated by the Enact segment. The company earns the maximum of its revenue in the United States.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: